Boehringer Ingelheim Partners with Sleip AI to Employ AI-technology to Diagnose Lameness in Equines
Shots:
- Boehringer Ingelheim has collaborated with Sleip AI to leverage the latter’s AI-based, Sleip app, for providing solutions enabling enhanced identification, diagnosis and treatment of lameness in horses
- The partnership aims to introduce the Sleip app into the veterinary community for improved care and well-being of horses. Boehringer will begin marketing of app in the US and Canada later in 2024 followed by the EU markets in 2025
- The Sleip app records horse’s actions and analyses them using AI to deliver the outcomes incl. stride-by-stride analysis video with synchronized biomechanical data within the app
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim
Related News:- Boehringer Ingelheim and Veeva Collaborate for Advancing Clinical and Regulatory Operations in Animal Health
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
